Wealth Alliance Sells 4,149 Shares of Pfizer Inc. (NYSE:PFE)

Wealth Alliance lowered its stake in Pfizer Inc. (NYSE:PFE) by 8.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,391 shares of the biopharmaceutical company’s stock after selling 4,149 shares during the period. Wealth Alliance’s holdings in Pfizer were worth $1,257,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Cumberland Partners Ltd bought a new stake in Pfizer in the fourth quarter valued at $2,032,000. Ieq Capital LLC boosted its holdings in Pfizer by 14.3% in the fourth quarter. Ieq Capital LLC now owns 320,472 shares of the biopharmaceutical company’s stock valued at $8,502,000 after acquiring an additional 40,117 shares in the last quarter. Emerald Advisors LLC boosted its holdings in Pfizer by 8.3% in the fourth quarter. Emerald Advisors LLC now owns 28,474 shares of the biopharmaceutical company’s stock valued at $755,000 after acquiring an additional 2,190 shares in the last quarter. Private Wealth Partners LLC boosted its holdings in Pfizer by 29.6% in the fourth quarter. Private Wealth Partners LLC now owns 579,849 shares of the biopharmaceutical company’s stock valued at $15,383,000 after acquiring an additional 132,312 shares in the last quarter. Finally, Good Life Advisors LLC boosted its holdings in Pfizer by 27.1% in the fourth quarter. Good Life Advisors LLC now owns 71,410 shares of the biopharmaceutical company’s stock valued at $1,895,000 after acquiring an additional 15,211 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Price Performance

NYSE PFE opened at $25.86 on Friday. The business’s fifty day moving average price is $26.28 and its 200-day moving average price is $27.44. The stock has a market capitalization of $146.52 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is 121.99%.

Analyst Ratings Changes

A number of analysts have recently commented on PFE shares. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.